198results about How to "Increase virulence" patented technology

The invention relates to avermectin B2a / 2b amine derivatives and derivative salts thereof, and a preparation method and an application of the avermectin B2a / 2b amine derivative salts. The avermectin B2a / 2b amine derivatives comprise six types of compounds. The avermectin B2a / 2b amine derivative salts are salts formed by reactions of the six types of avermectin B2a / 2b amine derivatives and organic acid and inorganic acid. The preparation method of the avermectin B2a / 2b amine derivative salts comprises the steps that: (1) avermectin B2a / 2b is subjected to a protective reaction with tert-butyl dimethyl chlorosilane or allyl chloroformate; (2) protected B2a / 2b is subjected to a reaction with an oxidant, such that an avermectin B2a / 2b ketone compound is obtained; (3) the ketone compound is subjected to an amination reaction, such that protected amine derivative is obtained; and (4) the protective agent is removed, such that B2a / 2b amine derivative is obtained; the derivative is subjected to a reaction with organic or inorganic acid, such that avermectin B2a / 2b amine derivative salt is obtained. According to the invention, avermectin B2 is adopted as a matrix for synthesizing avermectin B2a / 2b amine derivative and avermectin B2a / 2b amine derivative salt, such that avermectin B2 applciation range is widened.

Certain multi-cyclic compounds and compositions thereof are useful for reducing or inhibiting the growth of bacterial biofilms and for controlling bacterial biofilm infections. Such compounds and compositions are also useful in methods for reducing or inhibiting the growth of biofilms and for controlling bacterial biofilm infections involving biofilms.

The invention relates to the field of diagnosis of and vaccination against Streptococcal infections and to the detection of virulence markers of Streptococci. The invention discloses a method for modulating virulence of a Streptococcus, the method comprising modifying a genomic fragment of Streptococcus wherein the genomic fragment comprises at least a functional part of a fragment identifiable by hybridization in Streptococcus suis to a nucleic acid or fragment thereof as shown in FIG. 5.

The invention relates to an insecticidal gene cry2Ah-like with high toxicity on lepidoptera pests and an application thereof, and belongs to the technical field of biology. The protein sequences of insecticidal proteins Cry2Ah-like, Cry2Ah-likesp and Cry2Ah-likevp with high toxicity on the lepidoptera pests are respectively shown as SEQ ID NO. 1, SEQ ID NO. 2 and SEQ ID NO. 3. The new gene provided by the invention achieves the high toxicity on cotton bollworm and corn borer, enriches the insecticidal gene resources, shows the toxicity on relative pests by being applied to transform microbes and overcomes and postpones the drug resistance of the pests on engineering bacteria.

The prevention and treatment of influenza is described, by using passive immunization with antibodies (e.g. polyclonal, monoclonal, etc.) to one or more conserved influenza proteins. Both antibodies and fragments thereof are contemplated, raised against conserved proteins such as nucleoproteins.

Non-naturally occurring mycobacteria in the Mycobacterium tuberculosis complex are provided. These mycobacteria have a deletion of an RD1 region or a region controlling production of a vitamin, and exhibit attenuated virulence in a mammal when compared to the mycobacteria without the deletion. Also provided are non-naturally occurring mycobacteria that have a deletion of a region controlling production of lysine, and mycobacteria comprising two attenuating deletions. Vaccines comprising these mycobacteria are also provided, as are methods of protecting mammals from virulent mycobacteria using the vaccines. Also provided are methods of preparing these vaccines which include the step of deleting an RD1 region or a region controlling production of a vitamin from a mycobacterium in the M. tuberculosis complex.

Non-naturally occurring mycobacteria in the Mycobacterium tuberculosis complex are provided. These mycobacteria have a deletion of an RD1 region or a region controlling production of a vitamin, and exhibit attenuated virulence in a mammal when compared to the mycobacteria without the deletion. Also provided are non-naturally occurring mycobacteria that have a deletion of a region controlling production of lysine, and mycobacteria comprising two attenuating deletions. Vaccines comprising these mycobacteria are also provided, as are methods of protecting mammals from virulent mycobacteria using the vaccines. Also provided are methods of preparing these vaccines which include the step of deleting an RD1 region or a region controlling production of a vitamin or the amino acids leucine and lysine from a mycobacterium in the M. tuberculosis complex. Embodiments of these mycobacteria, vaccines and methods, encompassing mycobacteria comprising a leucine auxotrophy and a pantothenate auxotrophy, are also provided.

The invention relates to a berberine abamectin aqua which is characterized in that abamectin and berberine plant extract are composed into the aqua, wherein, the content of the abamectin is 1mg / L to 2mg / L and the content of the berberine plant extract is 45mg / L to 55mg / L. The berberine abamectin aqua, by composing two kinds of pesticides with different mechanisms of action, not only can be favorable to solving the drug resistance of pests but also can improve the property of each drug, i.e. the content of the abamectin is greatly reduced, while the toxicity of the abamectin against the pests and the control of the berberine plant extract over the pests are improved; simultaneously, the aqua takes water as basic material, thus solving the problems of flammability and hazard caused by organic solvents and avoiding poisoning people and livestock and polluting environment.